The FDA approved bluebird bio’s lentiviral vector (LVV) eli-cel Friday as the first therapy to slow the progression of neurologic dysfunction in juvenile boys with early, active cerebral adrenoleukodystrophy (CALD).
https://www.pharmalive.com/wp-content/uploads/2022/05/US-Bridging-Study-Not-Enough-as-FDA-Denies-Hutchmeds-Pancreatic-Cancer-Drug-BioSpace-5-2-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-09-19 10:55:112022-09-19 10:55:11Bluebird on a roll with second FDA approval in matter of weeks
